IL-17A and IL-17F antagonists
AssigneeZymoGenetics, Inc.
InventorsSteven D. Levin, Mark W. Rixon, Zeren Gao
Life of this patent
Estimating the term…
Abstract
The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.
Claims6
An isolated polypeptide comprising the amino acid sequence as shown in amino acid residues 32-811 of SEQ ID NO:140.
An isolated polypeptide produced by a method comprising:
- culturing a cell into which has been introduced an expression vector comprising a transcription promoter, a DNA segment encoding a polypeptide comprising the amino acid sequence as shown in amino acid residues 32-811 of SEQ ID NO:140, and a transcription terminator, wherein the cell expresses the polypeptide encoded by the DNA segment;
- and
- recovering the expressed polypeptide.
An isolated polypeptide produced by a method comprising:
- culturing a eukaryotic cell into which has been introduced an expression vector comprising a transcription promoter, a DNA segment encoding a polypeptide comprising a secretory signal sequence and the amino acid sequence as shown in amino acid residues 32-811of SEQ ID NO:140, and a transcription terminator, wherein the cell expresses the polypeptide encoded by the DNA segment, and wherein the expressed polypeptide is secreted from the cell;
- and
- recovering the expressed polypeptide.
A composition comprising:
- an isolated polypeptide comprising the amino acid sequence as shown in amino acid residues 32-811 of SEQ ID NO:140;
- and
- a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.